Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease
Alzheimer's & Dementia · 2026-06 · 22 (6)
DOI: 10.1002/alz.71573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 23.06.2026. Verfasst von Janice Wong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Alzheimer Disease, tau Proteins, Brain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson, Alzheimer's Disease Neuroimaging Initiative (ADNI), Johnson and Johnson.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Inhibition of pathological tau spread may slow cognitive decline in Alzheimer's disease. Here, we evaluate two tau positron emission tomography (PET) analysis methods designed for detecting tau spread. METHODS Spatial progression of tauopathy (SPOT) and tau‐naïve anatomical region of interest (tau‐naïve ROI) methods were assessed in two large observational cohorts in amyloid‐positive (A+) cognitively unimpaired (CU) or mildly cognitively impaired (MCI) participants versus CU amyloid‐negative (A−) participants. RESULTS SPOT and tau‐naïve ROI demonstrated measurable annualized change in CU A+ and MCI A+ participants versus CU A− participants. These spread estimates produced effect sizes comparable to standardized uptake value ratio (SUVR) change measures in anatomically defined ROIs. Effect sizes were increased when evaluating the subset of tau positive CU A+ and MCI A+ participants. DISCUSSION SPOT and tau‐naïve ROI methods are designed to measure tau spread and may be used in addition to traditional SUVR measures to evaluate tau progression in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johnson & Johnson, Cambridge, Massachusetts, USA.
- Johnson & Johnson, La Jolla, California, USA.
- Johnson & Johnson, Leiden, The Netherlands.
- Johnson & Johnson, Neuss, Germany.
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Förderung
- Johnson & Johnson
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Johnson and Johnson
Zitieren
APA
Wong, J., Wang, T., Datta, R., Abdollahi, R. O., Li, J., Rowe, C. C., Henley, D., Kolb, H. C., Saad, Z. S., & Alzheimer's Disease Neuroimaging Initiative (2026). Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease. Alzheimer's & Dementia, 22(6). https://doi.org/10.1002/alz.71573
Vancouver
Wong J, Wang T, Datta R, Abdollahi RO, Li J, Rowe CC, et al. Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease. Alzheimer's & Dementia. 2026;22(6). doi:10.1002/alz.71573
BibTeX
@article{Wong2026,
author = {Wong, Janice and Wang, Tina and Datta, Ritobrato and Abdollahi, Rouhollah O and Li, Jingwei and Rowe, Christopher C and Henley, David and Kolb, Hartmuth C and Saad, Ziad S and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {6},
doi = {10.1002/alz.71573}
}
EUVIMED